Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
AstraZeneca
Dow
Boehringer Ingelheim

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Guadecitabine


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Guadecitabine?

Guadecitabine is an investigational drug.

There have been 27 clinical trials for Guadecitabine. The most recent clinical trial was a Phase 3 trial, which was initiated on March 19th 2015.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Carcinoma. The leading clinical trial sponsors are Astex Pharmaceuticals, Astex Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are twenty US patents protecting this investigational drug and one hundred and sixty-two international patents.

Recent Clinical Trials for Guadecitabine
TitleSponsorPhase
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaNational Cancer Institute (NCI)Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Astex Pharmaceuticals, Inc.Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Bristol-Myers SquibbPhase 2

See all Guadecitabine clinical trials

Clinical Trial Summary for Guadecitabine

Top disease conditions for Guadecitabine
Top clinical trial sponsors for Guadecitabine

See all Guadecitabine clinical trials

US Patents for Guadecitabine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Guadecitabine ⤷  Try it Free Using DNA methyltransferase inhibitors to treat calcific aorta valve disease Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Try it Free
Guadecitabine ⤷  Try it Free Nucleotides for the treatment of liver cancer IDENIX PHARMACEUTICALS LLC (Cambridge, MA) ⤷  Try it Free
Guadecitabine ⤷  Try it Free Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in ovarian cancer UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) ⤷  Try it Free
Guadecitabine ⤷  Try it Free Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in lung cancer UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) ⤷  Try it Free
Guadecitabine ⤷  Try it Free SYK inhibitors GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Guadecitabine

Drugname Country Document Number Estimated Expiration Related US Patent
Guadecitabine Australia AU2014354775 2033-11-27 ⤷  Try it Free
Guadecitabine Brazil BR112016011949 2033-11-27 ⤷  Try it Free
Guadecitabine Canada CA2931458 2033-11-27 ⤷  Try it Free
Guadecitabine China CN105934438 2033-11-27 ⤷  Try it Free
Guadecitabine European Patent Office EP3074411 2033-11-27 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
AstraZeneca
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.